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Received August 31, 2011; accepted March 28, 2012AbstractBackground: The relationship between biochemical aspirin resistance (AR) and functional outcome of acute ischemic stroke is uncertain.
Methods: Prospectively, 269 patients with acute ischemic stroke were recruited. Their responsiveness to aspirin was evaluated by platelet
function analyzer (PFA-100). All patients received blood tests for fibrinogen, high-sensitivity C-reactive protein (hs-CRP), CD40-ligand,
P-selectin, intercellular adhesion molecule -1, von Willebrand factor (vWF), and Dedimer. The patients’ National Institutes of Health Stroke
Scale and modified Rankin Scale scores were recorded on admission, at 30 days, and at 90 days after stroke.
Results: Closure-time measured by PFA-100 equipped with epinephrine/collagen cartridge (Epi-CT) was <193 seconds (defined as AR) in 83
patients (30.9%). Patients with AR were less likely to have favorable outcome at 30 days (47.0%, p ¼ 0.047; odds ratio: 0.69, 0.48e0.99) and 90
days (57.8%, p ¼ 0.037; odds ratio: 0.69, 0.47e0.97) after stroke compared with those of patients without AR (60.2% and 71.0%, respectively).
The Epi-CT correlated with closure-time measured by adenosine diphosphate/collagen cartridge (r ¼ 0.241, p < 0.001), blood white cell count
(r ¼ 0.125, p ¼ 0.041), low density lipoprotein cholesterol (r ¼ 0.120, p ¼ 0.050), hs-CRP (r ¼ 0.150, p ¼ 0.015), vWF (r ¼ 0.134,
p ¼ 0.028), and body mass index (r ¼ 0.143, p ¼ 0.019). Multivariate logistic regression analysis showed that higher National Institutes of
Health Stroke Scale at admission, atrial fibrillation, increased plasma levels of hs-CRP, and Dedimer were independent predictors for unfa-
vorable stroke outcome at 90 days.
Conclusion: Aspirin resistance evaluated by PFA-100 test was associated with unfavorable 90-day outcome. However, AR determined by
PFA-100 dose not predict 90-day functional outcome. The results of PFA-100 testing represented a complex interaction between drug effect,
inflammatory reaction, and prothrombotic activity.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Platelet activation is a crucial mechanism in the patho-
physiology of ischemic stroke.1e3 Activated platelets release
various mediators and chemokines to recruit more activated* Corresponding author. Dr. Hung-Yi Hsu, Department of Internal Medicine,
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http://dx.doi.org/10.1016/j.jcma.2012.07.005platelets and leukocytes, which, in turn, accentuate local
thrombogenesis and inflammatory responses.1,3 Propagation of
thrombosis and inflammation might cause more injury to the
ischemic brain tissue and lead to poor outcomes.2 Several
markers of platelet activation were linked to poor outcomes of
acute ischemic stroke.2,4,5 Inhibition of platelet function is an
important therapeutic strategy in ischemic vascular diseases.
Aspirin is an important and effective therapeutic strategy in
secondary prevention of atherothrombotic events in acute
ischemic stroke.6 The bioavailability and responsiveness ofhinese Medical Association. All rights reserved.
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studies showed that 30%e40% of patients who experienced
ischemic stroke were taking aspirin at the time of their events.7
The so-called aspirin resistance (AR) or aspirin unrespon-
siveness is widely discussed in the literature, though few
studies focused on acute ischemic stroke patients.7e10 Effec-
tive antithrombotic management of acute ischemic stroke
depends on a better understanding of AR and its potential
influences on stroke outcomes.
The usefulness of in vitro tests for AR remains undeter-
mined.11 Among various platelet function tests, closure-time
(CT) measured by platelet function analyzer-100 (PFA-100,
Dade Behring, Marburg, Germany) equipped with collagen/
epinephrine cartridge is able to evaluate the response to aspirin
and is a point-of-care test among different tests of platelet
function.12,13 Aspirin resistance determined by PFA-100 has
shown that AR was associated with a higher risk of future
cardiovascular events.14,15 Aspirin resistance assessed by
PFA-100 occurred in approximately 15%e60% of patients
with ischemic stroke, depending on the age, the history of
diabetes and hypertension, and the acuteness of the ischemic
event.7,16,17 Recent studies demonstrate that CT measured by
PFA-100, as an indicator of platelet functions, might help in
guiding antiplatelet therapy.18 The role of PFA in assessing
platelet activation during the acute stage of ischemic stroke
has only been evaluated in a few studies.7,9,10 The prognostic
significance of AR in acute stroke patients is also rarely
reported.10 Whether AR assessed by PFA-100 or humoral
markers of platelet activation during the acute stroke period
could predict patient outcome, or the likelihood of recurrent
ischemic events is of interest. We conducted this study to
evaluate the relationship between AR, plasma markers asso-
ciated with platelet activation, and outcomes in patients with
acute ischemic stroke.
2. Methods2.1. ParticipantsFrom Feb 1, 2005, to July 31, 2006, a total of 347 consec-
utive patients who were admitted to this hospital due to
ischemic stroke within 7 days after onset were prospectively
screened by experienced neurologists. All stroke patients ful-
filled the World Health Organization criteria of stroke and had
no evidence of hemorrhage on their cranial computed
tomography or magnetic resonance imaging. Patients were
excluded due to: (1) having used anticoagulants for secondary
prevention (29 patients), (2) having contraindication for
aspirin use (21 patients), (3) other known causes of ischemic
stroke (arterial dissection in four patients, protein C deficiency
in two patients, anticardiolipin syndrome in two patients,
hypercoagulation state due to malignancy in one patient), (4)
severe renal or hepatic diseases (10 patients), (5) hematocrit
less than 30% (11 patients), (6) platelet count less than
100,000/cumm limbs (five patients), and (7) allergy to aspirin
(three patients). After screening was completed, 269 patients
were enrolled into this study. The study was approved by theinstitutional review committee of this hospital and all enrolled
participants gave informed consent before entering this study.
We recorded patient medical histories, cardiovascular risk
factors, and currently used medications. Ancillary tests (chest
radiography, electrocardiography, complete blood cell count,
prothrombin time, activated partial thromboplastin time,
fibrinogen, fasting plasma sugar, and routine biochemical
tests) were further performed on all studied patients. In addi-
tion, all recruited patients received duplex sonography of
cervical arteries and transcranial color-coded sonography.
Echocardiography was performed if there was an abnormal
electrocardiographic finding or finding on physical examina-
tion suggesting organic cardiac disease. Twenty-four-hour
Holter electrocardiography was performed if paroxysmal
arrhythmia was clinically suspected. All stroke patients were
classified into different stroke subgroups based on results of
the aforementioned investigations and criteria adapted from
the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
study.19 National Institutes of Health Stroke Scale (NIHSS)
and modified Rankin Scale (mRS) scores were recorded on
admission, 30 days, and 90 days after the index stroke for all
recruited patients. The stroke outcome was dichotomized by
mRS for statistic analysis. A mRS  2 was defined as favor-
able outcome, and a mRS > 2 was defined as unfavorable
outcome.
All patients received 100 mg aspirin (standard form or
enteric-coated form) per day for at least 5 days before being
tested for platelet function and plasma markers. Venous blood
was obtained by venipuncture at the forearm by 21-gauge
needle for all participants after an overnight fast. Whole
blood samples for platelet function study were anticoagulated
with 3.8% sodium citrate and were analyzed immediately.
After centrifugation, the citrated plasma samples were then
stored at 70C until further measurements were necessary.
Platelet function was studied by using the PFA-100 device.
The PFA-100 device measured the time necessary to form
a hemostatic platelet plug and to occlude the central hole of an
epinephrine/collagen- or adenosine diphosphate/collagen-
coated membrane, which is called “closure time” and is
related to platelet function.12 These results were recorded as
epinephrine closure-time (Epi-CT) and adenosine diphosphate
closure-time (ADP-CT). Patients who had an Epi-CT <193
seconds were classified as AR.20
Commercial enzyme-linked immunoassay test kits were
used to measure plasma concentrations of high sensitive
C-reactive protein (hs-CRP), soluble P-selectin, soluble CD40-
ligand (sCD40L), soluble intercellular adhesion molecule-1
(ICAM-1), von Willebrand factor (vWF), and Dedimer. Test
kits from R&D Systems, Inc. (Minneapolis, MN, USA) were
used for measuring P-selectin, sCD40L, hs-CRP, and ICAM-1,
and test kits from American Diagnostica, Inc. (Stamford, CT,
USA) were used for measuring vWF and Dedimer.2.2. Statistical analysisContinuous variables are expressed as mean  standard
deviation. Nonparametric Mann-Whitney test was used to
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between patients with favorable outcomes and unfavorable
outcomes. Chi-square test was used for evaluating categorical
variables. The Spearman rank correlation coefficient was used
to evaluate the relationship between Epi-CT and other studied
parameters. Univariate and multivariate logistic stepwise
regression analysis were used to evaluate the relationship
between stroke outcome and studied parameters. Age, sex, and
AR were forced into the multivariate regression model in order
to assess their influence. All statistical calculations were
performed using a commercially available statistical package
(SPSS 13.0 for Windows, SPSS Inc., Chicago, IL, USA). A p
value less than 0.05 was considered statistically significant.
3. Results
The study population consisted of 70 women (26%) and
199 men, and they had a mean age of 68.7  12.2 years
(range: 21e91 years). Hypertension was observed in 210
patients (78.1%), diabetes in 99 patients (36.8%), hyperlipid-
emia in 71 patients (26.4%), history of previous transient
ischemic attack or stroke in 141 patients (52.4%), coronary
heart disease in 81 patients (30.1%), and current smoking
status in 106 patients (39.4%); AR was observed in 83 patients
(30.9%). The frequencies of AR in TOAST stroke subtypesTable 1
Comparison of clinical profiles and laboratory data between patients with and wit
Aspirin resistance (n ¼ 83)
Age (yr) 69.6  11.1
Sex (male/female) 62/21
Coronary heart diseases (%) 25 (30.1%)
Previous stroke or transient ischemic attack (%) 42 (51.9%)
Atrial fibrillation (%) 10 (12.0%)
Hypertension (%) 61 (73.5%)
Diabetes mellitus (%) 27 (32.5%)
Hyperlipidemia (%) 23 (27.7%)
Smoking (%) 38 (45.8%)
NIHSS at admission 7.7  6.0
Body mass index 24.0  3.2
Pre-ASA (%) 49 (26.3%)
Fibrinogen (g/L) 4.09  0.51
hs-CRP (mg/L) 1.4  2.5
Dedimer (mg/L) 1.09  1.49
vWF (mU/mL) 1,930  891.8
ICAM (ng/mL) 293.7  176.4
CD40 ligand (ng/mL) 4.64  3.16
P-selectin (ng/mL) 99.7  28.8
Stroke outcome
At 7 days
mRS  2 27 (32.5%)
mRS > 2 56 (67.5%)
At 30 days
mRS  2 39 (47.0%)
mRS > 2 44 (53.0%)
At 90 days
mRS  2 48 (57.8%)
mRS > 2 35 (42.2%)
hs-CRP ¼ high-sensitivity C-reactive protein; ICAM ¼ intercellular adhesion mol
Stroke Scale; OR ¼ odd ratios for aspirin non-responder to have mRS  2; pre-Awere 33.0% (31 of 93) for atherothrombotic stroke, 42% (eight
of 19) for cardioembolic stroke, 27.0% (26 of 95) for small
vessel disease, and 29% (18 of 44) for undetermined cause
(overall p < 0.001). Enteric-coated aspirin was not associated
with AR. The demographic characteristics, National Institutes
of Health Stroke Scale (NIHSS) at admission, and plasma
levels of the previously mentioned factors were not different
between patients with and without AR (Table 1). The outcome
data at 90 days were not available in three patients without
AR. Patients with AR were less likely to have favorable
outcome at 30 days (47.0%, p ¼ 0.047, odds ratio: 0.69,
0.48e0.99) and 90 days (57.8%, p ¼ 0.037, odds ratio: 0.69,
0.47e0.97) after stroke compared with those of patients
without AR (60.2% and 71.0%, respectively). Recurrent
ischemic stroke occurred in three patients (3.6%) with AR and
seven patients (3.8%) without AR ( p ¼ 1.000) during a 90-day
follow-up. The Epi-CT significantly correlated with ADP-CT
(r ¼ 0.241, p < 0.001), white cell count (r ¼ 0.125,
p ¼ 0.041), low density lipoprotein cholesterol (r ¼ 0.120,
p ¼ 0.050), hs-CRP (r ¼ 0.150, p ¼ 0.014), vWF
(r ¼ 0.134, p ¼ 0.028), and body mass index (BMI;
r ¼ 0.143, p ¼ 0.019).
The clinical and laboratory profiles of patients with favor-
able outcome and unfavorable outcome are shown in Table 2.
Unfavorable stroke outcomes were associated with older age,hout aspirin resistance.
Aspirin responder (n ¼ 186) p value
68.3  12.8 0.447
137/49 0.882
56 (30.1%) 1.000
99 (55.9%) 0.591
17 (9.1%) 0.512
149 (80.1%) 0.264
72 (38.7%) 0.342
48 (25.9%) 0.766
68 (36.6%) 0.177
6.7  4.7 0.453
24.8  2.9 0.084
22 (26.5%) 1.000
4.20  0.99 0.309
1.0  1.7 0.133
1.00  1.70 0.678
1,746  836.5 0.105
332.4  659.3 0.599
4.40  2.99 0.544
101.3  44.6 0.805
71 (38.2%) p ¼ 0.412; OR ¼ 1.08, (0.57e1.24)
115 (61.8%)
112 (60.2%) p ¼ 0.047; OR ¼ 1.183, (1.00e1.40)
74 (39.8%)
132 (71.0%) p ¼ 0.037; OR ¼ 1.21, (1.01e1.46)
54 (29.0%)
ecule; mRS ¼ modified Rankin Scale; NIHSS = National Institutes of Health
SA ¼ aspirin use prior to the index stroke; vWF ¼ von Willebrand factor.
Table 2
Comparison of clinical profiles between patients with favorable (mRS & 2) and unfavorable 90-day outcome (mRS > 2).
Favorable outcome (n ¼ 180) Unfavorable outcome (n ¼ 89) p value
Age (yr) 66.6  12.7 73.0  10.0 <0.001
Sex (female/male) 38/142 32/57 0.012
Coronary heart disease (%) 43 (23.9%) 38 (42.7%) 0.002
Previous stroke or transient ischemic attack (%) 90 (50%) 51 (57.3%) 0.143
Atrial fibrillation (%) 8 (4.4%) 19 (21.3%) <0.001
Hypertension (%) 137 (76.1%) 73 (82.0%) 0.347
Diabetes mellitus (%) 66 (36.7%) 33 (37.1%) 1.000
Hyperlipidemia (%) 54 (30%) 17 (19.1%) 0.057
Smoking (%) 72 (40%) 34 (38.2%) 0.792
NIHSS at admission 5.4  4.0 11.4  6.2 <0.001
Body mass index 25.0  3.0 23.7  2.9 0.002
Pre-ASA (%) 53 (29.4%) 18 (20.2%) 0.141
Aspirin resistance (%) 48 (27.7%) 35 (39.3%) 0.035
Fibrinogen (g/L) 4.12  0.81 4.25  0.97 0.263
Dedimer (mg/L) 0.73  0.95 1.64  2.40 <0.001
hs-CRP (mg/L) 0.8  1.4 1.8  2.7 0.001
vWF (mU/mL) 1,708  839.6 1,996.1  862.5 0.009
ICAM-1 (ng/mL) 273.5  110.6 415.4  951.4 0.049
CD40-ligand (ng/mL) 4.50  3.07 4.43  2.97 0.853
P-selectin (ng/mL) 101.0  45.0 100.2  29.0 0.876
Aspirin resistance ¼ a epinephrine/collagen closure-time > 193 seconds; hs-CRP ¼ high-sensitivity C-reactive protein; ICAM ¼ intercellular adhesion molecule;
NIHSS = National Institutes of Health Stroke Scale; pre-ASA ¼ aspirin use prior to the index stroke; vWF ¼ von Willebrand factor.
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lation, lower BMI, higher NIHSS score at admission, AR, and
higher plasma concentrations of hs-CRP, Dedimer, vWF, and
ICAM-1 (Table 2). Multivariate logistic stepwise regression
analysis showed that NIHSS score at admission, atrial fibril-
lation, increased plasma levels of hs-CRP, and Dedimer were
independent predictors for unfavorable 90-day outcome. The
predictive power of AR became insignificant when hs-CRP
was put into the regression model as a predictor for 90-day
outcome. AR remained an insignificant factor in the final
regression analysis after adjusting for age and sex (Table 3).
4. Discussion
Our study demonstrated that biochemical AR, as evaluated
by Epi-CT on PFA-100, is a common condition in acute
ischemic stroke patients. The prevalence of AR in our patientsTable 3
Independent predictors for unfavorable outcome by multivariate logistic
regression analysis.
B SE p value Odds ratio (95% CI)
Age (yr) 0.028 0.020 0.154 1.029 (0.989e1.070)
Sex (female as baseline) 0.797 0.436 0.067 0.451 (0.192e1.059)
NIHSS at admission 0.221 0.038 <0.001 1.245 (1.148e1.345)
hs-CRP (mg/dL) 0.233 0.107 0.039 1.262 (1.023e1.556)
Atrial fibrillation 1.379 0.633 0.029 3.973 (1.148e13.745)
Dedimer 0.232 0.133 0.042 1.346 (1.122e1.639)
Aspirin resistance 0.198 0.452 0.662 0.820 (0.338e1.991)
Constant 0.071 2.740 0.979 0.931
B ¼ B coefficient; CI ¼ confidence interval; hs-CRP ¼ high-sensitivity C
reactive protein; NIHSS ¼ National Institutes of Health Stroke Scale;
SE ¼ standard error.was lower than those observed in other studies using Epi-CT in
acute ischemic stroke patients.9,18 A low noncompliance rate
and ethnic difference in responsiveness and bioavailability to
aspirin may contribute to the lower prevalence of AR in our
patients. Enteric-coated aspirin was not associated with higher
frequency of AR in our study in contrast to previous study.18
The lipid profile and vascular risk factors were different
between patients with and without AR.
AR was associated with unfavorable 30-day and 90-day
outcome in our patients. More interestingly, the predictors
for 90-day outcome in multivariate regression analysis
included NIHSS score, atrial fibrillation, plasma levels of
hs-CRP, and D-dimer, but not AR. The Epi-CT significantly
correlated with hs-CRP. Although AR was associated with
unfavorable outcome in univariate analysis, the predictive
power of AR (as defined by Epi-CT) was overridden by the
power of hs-CRP in the regression model.
CRP is an inflammatory marker, and it is associated with
various cardiovascular diseases. Infection may precipitate an
ischemic stroke attack.3 On the other hand, infectious
complications during acute ischemic stroke period have an
adverse effect on stroke recovery.21 Only a few patients (two
patients with AR and one patient with non-AR) in our study
had fever and CRP higher than 4.0 mg/dL, which suggested
substantial infection at the time of blood test. We did not have
enough data to comment on the relationship between infection
and stroke outcome. The higher plasma concentration of CRP
was associated with larger brain infarcts and a worse neuro-
logic outcome.22 Some published data linked inflammation
with AR.22e24 Inflammation, as represented by elevated CRP
level, could accentuate platelet activation, and cytokines
released by activated platelets could induce inflammatory
responses. Both inflammation and platelet activation play
517P.-T. Lai et al. / Journal of the Chinese Medical Association 75 (2012) 513e518important roles in acute ischemic vascular events. Inflamma-
tion and AR are not mutually exclusive, but rather two com-
plementing elements of ischemic brain damage.24 CRP and
D-dimer were independent predictors of poor stroke outcome
in other studies.25,26 However, the usefulness of Dedimer in
predicting stroke outcome needs more study.27
The ADP-CT measured by PFA-100 is not affected by the
use of aspirin.28 The significant correlation between ADP-CT
and Epi-CT suggested that AR in our patients might result
from abnormal platelet activation through noncyclooxygenase-
mediated mechanisms. The PFA-100 test may unveil other
biological factors that contribute to shortening Epi-CT, not
necessarily resistant to aspirin. The results of the PFA-100 test
represent the global status of platelet activation via various
mechanisms including inadequate suppression effect of drug,
systemic inflammation, and prothrombotic activity.
Meta-analysis studies showed that patients who had labo-
ratory AR are more likely to have clinical ischemic
events.14,15,29 On the contrary, AR measured by PFA-100 did
not predict new thrombotic event in patients with stable
cardiovascular diseases in other studies.30e32 The frequency of
previous history of stroke or transient ischemic attack was not
different between our patients with and without AR. The
discrepancies between studies could result from the fact that
some studies recruited patients with chronic stable stroke and
some studies recruited patients with acute ischemic stroke.17
Cohort study also demonstrated that the prevalence of AR
decreased during follow-up tests.9,33 The recurrent ischemic
vascular events during a 90-day follow-up in our study were
too few to draw any conclusions.
The relationship between different stroke subtypes and AR
was unclear.10,22,34,35 Previous study showed that AR
occurred more frequently in lacunar stroke.22 Our patients
with cardioembolic stroke had a higher percentage of AR
(seven of the eight patients with AR had atrial fibrillation),
and increased platelet activation in patients with atrial fibril-
lation had also been reported.4,36 Atrial fibrillation is associ-
ated with inflammation and coagulation cascade activation.37
Inflammatory cytokines and activated coagulation factors such
as thrombin could subsequently activate more platelets.
Patients with atrial fibrillation could have high residual
platelet aggregability, which was mediated through a non-
cyclooxygenase pathway and could not be suppressed by
aspirin. Clinically, an oral anticoagulant is more effective than
aspirin in preventing recurrent ischemic stroke for patients
with atrial fibrillation.
The PFA-100 results are strongly correlated with vWF in
our study and previous reports.38 VWF is also a marker of
cardiovascular risk and an independent risk factor for recurrent
myocardial infarctions and death.39 Plasma vWF level was
significantly higher in patients with unfavorable outcome in
our study. Plasma levels of P-selectin, ICAM-1, and CD40
ligand were not associated with stroke outcome in our study.
The application of these parameters in daily clinical practice is
limited, partly because of insufficient reproducibility and the
expense of time and required equipment. More studies are
necessary to prove whether these markers could predictfunctional outcomes after stroke and could be helpful to guide
therapeutic decisions.
There are some limitations of this study. The study evalu-
ated the short-term outcome only during a 90-day follow-up.
The relationship between long-term outcome and AR was
not studied. Furthermore, higher dose of aspirin was not
allowed in this study. Another methodical problem is artifac-
tual in vitro activation of platelets during blood sampling and
processing.
In conclusion, AR evaluated by PFA-100 was associated
with unfavorable 30- and 90-day stroke outcome, but it was
not predictive of 90-day functional outcome in patients with
acute ischemic stroke. NIHSS score at admission, atrial
fibrillation, and plasma levels of hs-CRP and Dedimer were
predictors of 90-day outcomes. The results of PFA-100 test
represented an overall effect of platelet inhibition by drug,
systemic inflammation, and prothrombotic activity.Acknowledgments
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